Zobrazeno 1 - 7
of 7
pro vyhledávání: '"M. K. Brun"'
Autor:
K Bjørlykke, M K Brun, M K Viken, G E Stenvik, R A Klaasen, J E Gehin, D J Warren, J Sexton, E A Haavardsholm, J Jahnsen, B A Lie, G L Goll, N Bolstad, S W Syversen, K K Jørgensen
Publikováno v:
Journal of Crohn's and Colitis. 16:i594-i595
Background Immunogenicity is a leading cause of treatment failure to TNF inhibitors. Genetic variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation, but studies using high-resolution HLA typing as well as c
Autor:
M. K. Brun, K. H. Bjørlykke, M. K. Viken, B. Stenvik, R. A. Klaasen, J. Gehin, D. J. Warren, J. Sexton, Ø. Sandanger, C. Mørk, T. K. Kvien, E. A. Haavardsholm, J. Jahnsen, G. L. Goll, B. A. Lie, K. K. Jørgensen, N. Bolstad, S. W. Syversen
Publikováno v:
Annals of the Rheumatic Diseases. 81:216.2-217
BackgroundImmunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation (ADA), but characterisation of biolog
Autor:
K K Jørgensen, S W Syversen, G L Goll, K H Bjørlykke, Ø Sandanger, J Sexton, M K Brun, G Noraberg, C M Ystrøm, K A Seeberg, I M Blomgren, R Torp, C Mørk, T K Kvien, N Bolstad, E A Haavardsholm, J Jahnsen
Publikováno v:
Journal of Crohn's and Colitis. 16:i010-i010
Background Proactive therapeutic drug monitoring (TDM), individualized treatment based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety of infliximab and other biologic drugs. However, it is unclear whe
Autor:
David J. Warren, Silje W Syversen, K. K. Jørgensen, Nils Bolstad, C. Mørk, Joseph O. Sexton, Rolf Anton Klaasen, T.K. Kvien, M. K. Brun, Øystein Sandanger, Inge C. Olsen, G. L. Goll, Jørgen Jahnsen, J. E. Gehin, Espen A Haavardsholm
Publikováno v:
Annals of the Rheumatic Diseases. 80:185.2-185
Background:Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate of anti-drug antibody (ADAb) formation has been reported for infliximab (IFX). 1 Knowle
Autor:
Silje W Syversen, G. L. Goll, Espen A Haavardsholm, K. K. Jørgensen, Inge C. Olsen, Joseph O. Sexton, T.K. Kvien, Jørgen Jahnsen, Nils Bolstad, C. Mørk, David J. Warren, M. K. Brun, J. E. Gehin, Øystein Sandanger
Publikováno v:
Annals of the Rheumatic Diseases. 79:12-12
Background:A lack or loss of response to TNFα inhibitors (TNFi) has been associated with low serum drug levels and formation of anti-drug antibodies (ADAb). Therapeutic drug monitoring (TDM), an individualised treatment strategy based on regular ass
Autor:
K. Grjotheim, M. K. Brun
Publikováno v:
Canadian Metallurgical Quarterly. 16:161-165
Flood-Grjotheim thermodynamic treatment of slag-metal exchange equilibria has been applied to the experimental results of several authors investigating phosphorous and manganese distribution between slags and molten metal.For the phosphorous reaction
Publikováno v:
Journal of the American Ceramic Society. 58:392-395